Lumira Ventures is a venture capital firm that specializes in investments in the life sciences sector, including biotechnology, pharmaceuticals, and healthcare IT. The firm focuses on early-stage companies with innovative technologies and therapeutics that have the potential to address significant unmet medical needs.

Lumira Ventures

New England Venture Network is an organization of over 600 venture capitalists in Boston and greater New England designed to foster a vibrant and connected community in the area. The organization focuses on building relationships among peers and improving the New England technology and investment landscape in high tech, life science, and clean tech.

New England Venture Network

Lumira Ventures is a leading healthcare and life sciences venture capital firm, investing in innovative innovative entrepreneurs developing best and first-in-class therapeutics & medical technologies across North America. We are engaged partners who support the management teams of companies we invest in to build products that have the potential to allow people to lead fundamentally healthier, longer and more productive lives.

Looking forward to #THT2024 in Boston and a number of clinical data readouts from Lumira Ventures' portfolio companies innovating the standard of care for heart failure.  

Looking forward to seeing some of you at the BIO CEO & Investor Conference in New York City this week.  

Canadian business, #healthcare, #government and #academic communities have developed many of the ingredients needed to create a world-class #healthcare #innovation ecosystem, but there is still work to be done.

We explore this and other key topics in this discussion with Peter van der Velden, Jacki Jenuth and Suman Rao of Lumira Ventures. https://bit.ly/49cQ1yF

Major Milestone: Lumira portfolio company, Iterion Therapeutics, has dosed the first patient in the phase 1b/2a clinical trial of Tegavivint in advanced hepatocellular carcinoma.

Read more: https://bit.ly/3ORo8UH

Lumira Ventures was among over 15 new and existing investors participating in the $200M oversubscribed private placement financing of our portfolio company enGene (Nasdaq: ENGN). The financing will help fund the company's operating plan into 2027.

Read more: https://bit.ly/4bFPCXa


Metric
Company Name	Lumira Ventures	New England Venture Network
Symbol
MSH ID	COM:LUMIRAVENTURES	ORG:NEVN
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Commercial & Professional Services
Industry	Biotechnology and Pharmaceuticals	Investment & Venture Capital
Country	CA	US
Stage
Employee Count	23
Website	lumiraventures.com	nevn.org
LinkedIn	lumiraventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:LUMIRAVENTURES

Lumira Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue